Profound Medical (PROF) announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the Company’s TULSA-PRO system. The milestone marks the official launch of TULSA-PRO at one of the world’s most influential centers for prostate cancer innovation and coincides with the opening of Johns Hopkins Medicine’s new interventional MRI suite.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical Raises US$6.45 Million in Canadian Private Placement
- Profound Medical Upsizes Private Placement to Raise US$6.45 Million
- Profound Medical Raises $36 Million in Equity Financing, Plans Additional Private Placement
- Profound Medical Launches Up to $40 Million Equity Financing to Support Growth
- Profound Medical prices 5.14M shares at $7.00 in registered direct offering